10X Genomics, a Bay Area startup that’s building out extensive next-generation sequencing services, just closed out a $55 million Series C round – meant largely to fuel sales and marketing growth.
Investors include Fidelity Management, Softback, JS Capital Management, Venrock, Foresite Capital, and Paladin Capital.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company’s product suite uses whole genome sequencing, single gene expression analysis and careful exome analysis to unveil new structural variants and haplotypes – thus painting a broader picture of human health. It sells instruments, reagents and software to make sense of a huge swath of sequenced genetic data.
Notably, last month 10X Genomics signed a comarketing agreement with Illumina to promote its Linked-Read sequencing products.